GlassScriptPhysician profile
Benjamin A Cooperberg
NPI 1760604037
$401.91
in general payments reported to CMS, 2019-2025
9 companies · $23.33 in 2025
The $23.33 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.84 · 2021: $27.92 · 2022: $56.04 · 2023: $249 · 2024: $24.00 · 2025: $23.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $236.71 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $144.78 | 2022-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $65.67 | 2023 | Tymlos |
| Mannkind Corporation | $59.40 | 2023 | Afrezza |
| Tandem Diabetes Care, INC. | $44.73 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $31.67 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $16.25 | 2021 | |
| Cequr Corporation | $13.93 | 2023 | Cequr Simplicity |
| Tolmar, INC. | $13.77 | 2023 | |
| Lilly USA, LLC | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Cooperberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.